3
Participants
Start Date
May 31, 2009
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2012
Dasatinib and Rituximab
"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
University of California San Diego Moores Cancer Center, La Jolla
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of California, San Diego
OTHER